造血及淋巴系统肿瘤凝血致活物监测及临床分析

Thromboplatinogen within hematopoietic and lymphatic cancer patients and discuss the clinical significance.

目的观察造血及淋巴系统肿瘤患者凝血致活物治疗前后的变化，探讨其临床意义。方法用ELISA法测定血管性假血友病因子、血小板颗粒膜糖蛋白、纤维蛋白肽A、蛋白C、D2聚体；用磁珠法测定纤维蛋白原。结果造血及淋巴系统肿瘤患者治疗前VMF、FPA、FG、GMP-140、P—C、D2聚体均明显升高，治疗缓解后明显下降。结论造血及淋巴系统肿瘤患者体内存在止、凝血功能异常，可随病情好转而改变。

Objective To observe the change before and after the treatment of thromboplatinogen within hematopoietic and lymphatic cancer patients and discuss the clinical significance. Methods By ELISA method to measure yon - willebrand factor VWF, GMP - 140, FPA, P-C,D2 -Dimer and measure Fg. Results VMF, FPA, FG, GMP - 140, P - C, D2 - Dimer of hematopoietic and lymphatic cancer patients were significantly increased before the treatment and significantly decreased after treatment of mitigation. Conclusion There is coagulation dysfunction in hematopoietic and lymphatic cancer patients, it can get better with the condition improved.